Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Benner

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancerVera Hirsh, Luis Paz-Ares, Michael Boyer, et al.
Cell Stem Cell|August 4, 2023
20-αHydroxycholesterol, an oxysterol in human breast milk, reverses mouse neonatal white matter injury through Gli-dependent oligodendrogenesisAgnes S Chao, Pavle Matak, Kelly Pegram, et al.
Cell Stem Cell|March 27, 2024
Subventricular zone stem cell niche injury is associated with intestinal perforation in preterm infants and predicts future motor impairmentAdrian A Epstein, Sara N Janos, Luca Menozzi, et al.
Journal of Neonatal-Perinatal Medicine|April 18, 2022
Proceedings of the 13th International Newborn Brain Conference: Fetal and/or neonatal brain development, both normal and abnormalKhadar Abdi, Ramy Abramsky, Nickie Andescavage, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancerVera Hirsh, Luis Paz-Ares, Michael Boyer, et al.
Cell Stem Cell|August 4, 2023
20-αHydroxycholesterol, an oxysterol in human breast milk, reverses mouse neonatal white matter injury through Gli-dependent oligodendrogenesisAgnes S Chao, Pavle Matak, Kelly Pegram, et al.
Cell Stem Cell|March 27, 2024
Subventricular zone stem cell niche injury is associated with intestinal perforation in preterm infants and predicts future motor impairmentAdrian A Epstein, Sara N Janos, Luca Menozzi, et al.
Journal of Neonatal-Perinatal Medicine|April 18, 2022
Proceedings of the 13th International Newborn Brain Conference: Fetal and/or neonatal brain development, both normal and abnormalKhadar Abdi, Ramy Abramsky, Nickie Andescavage, et al.
Pageof 11